Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

457 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond.
Menezes MCS, Raheem F, Mina L, Ernst B, Batalini F. Menezes MCS, et al. Among authors: ernst b. Cancers (Basel). 2022 Sep 5;14(17):4332. doi: 10.3390/cancers14174332. Cancers (Basel). 2022. PMID: 36077867 Free PMC article. Review.
Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round.
Patel BK, Carnahan MB, Northfelt D, Anderson K, Mazza GL, Pizzitola VJ, Giurescu ME, Lorans R, Eversman WG, Sharpe RE Jr, Harper LK, Apsey H, Cronin P, Kling J, Ernst B, Palmieri J, Fraker J, Mina L, Batalini F, Pockaj B. Patel BK, et al. Among authors: ernst b. J Clin Oncol. 2024 Nov 10;42(32):3826-3836. doi: 10.1200/JCO.22.02819. Epub 2024 Jul 26. J Clin Oncol. 2024. PMID: 39058970
Lifestyle Factors and Cancer: A Narrative Review.
Sharman R, Harris Z, Ernst B, Mussallem D, Larsen A, Gowin K. Sharman R, et al. Among authors: ernst b. Mayo Clin Proc Innov Qual Outcomes. 2024 Mar 4;8(2):166-183. doi: 10.1016/j.mayocpiqo.2024.01.004. eCollection 2024 Apr. Mayo Clin Proc Innov Qual Outcomes. 2024. PMID: 38468817 Free PMC article.
A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma.
Padrnos L, Ernst B, Dueck AC, Kosiorek HE, Ginos BF, Toro A, Johnston PB, Habermann TM, Leis JF, Mikhael JR, Nowakowski GS, Colgan J, Porrata L, Ansell SM, Witzig TE, Reeder C. Padrnos L, et al. Among authors: ernst b. Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):664-672.e2. doi: 10.1016/j.clml.2018.06.013. Epub 2018 Jun 15. Clin Lymphoma Myeloma Leuk. 2018. PMID: 30104176 Clinical Trial.
457 results